Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11175MR)

This product GTTS-WQ11175MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11175MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8890MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ3870MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ8785MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IBI-306
GTTS-WQ15802MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ9771MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ14720MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ951MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ2276MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN1007
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW